Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study
There are increasing efforts to better predict adverse outcomes for idiopathic pulmonary fibrosis (IPF). Our aim was to assess the prognostic potential of ischemia-modified albumin (IMA), an established circulating marker of ischemia and, more recently, oxidative stress, in a cohort of 56 IPF patien...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/13/3/278 |
| _version_ | 1827307278570618880 |
|---|---|
| author | Angelo Zinellu Stefano Zoroddu Simona Fois Sabrina Mellino Chiara Scala Erika Virdis Elisabetta Zinellu Salvatore Sotgia Panagiotis Paliogiannis Arduino A. Mangoni Ciriaco Carru Pietro Pirina Alessandro G. Fois |
| author_facet | Angelo Zinellu Stefano Zoroddu Simona Fois Sabrina Mellino Chiara Scala Erika Virdis Elisabetta Zinellu Salvatore Sotgia Panagiotis Paliogiannis Arduino A. Mangoni Ciriaco Carru Pietro Pirina Alessandro G. Fois |
| author_sort | Angelo Zinellu |
| collection | DOAJ |
| description | There are increasing efforts to better predict adverse outcomes for idiopathic pulmonary fibrosis (IPF). Our aim was to assess the prognostic potential of ischemia-modified albumin (IMA), an established circulating marker of ischemia and, more recently, oxidative stress, in a cohort of 56 IPF patients recruited between 2015 and 2023 at the University of Sassari, Italy. Demographic and functional parameters and serum IMA concentrations were measured at baseline. Non-survivors had significantly higher IMA concentrations vs. survivors (508 ± 64 vs. 474 ± 42 mABSU, respectively; <i>p</i> = 0.035). The Kaplan–Meier analysis showed a significant association between higher IMA values and poor survival (HR: 3.32, 95% CI from 1.06 to 10.4, <i>p</i> = 0.039). In the Cox regression analysis, this association remained significant after adjusting for the force expiratory volume at 1 s, the total lung capacity, lymphocyte count, and pharmacological treatment (HR: 1.0154, 95% CI from 1.0035 to 1.0275, <i>p</i> = 0.01). IMA, an oxidative stress biomarker measurable using relatively simple and available methods, is independently associated with mortality in IPF. Therefore, its determination may enhance risk stratification and treatment decisions. Prospective studies involving larger cohorts are needed to confirm this association and to endorse the use of IMA in routine practice. |
| first_indexed | 2024-04-24T18:36:32Z |
| format | Article |
| id | doaj.art-47cb9d5fb045450781c9afe4b8fc6ad1 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-04-24T18:36:32Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-47cb9d5fb045450781c9afe4b8fc6ad12024-03-27T13:18:26ZengMDPI AGAntioxidants2076-39212024-02-0113327810.3390/antiox13030278Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot StudyAngelo Zinellu0Stefano Zoroddu1Simona Fois2Sabrina Mellino3Chiara Scala4Erika Virdis5Elisabetta Zinellu6Salvatore Sotgia7Panagiotis Paliogiannis8Arduino A. Mangoni9Ciriaco Carru10Pietro Pirina11Alessandro G. Fois12Department of Biomedical Sciences, University of Sassari, 07100 Sassari, ItalyDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, ItalyDepartment of Respiratory Diseases, University Hospital Sassari (AOU), 07100 Sassari, ItalyDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, ItalyDepartment of Respiratory Diseases, University Hospital Sassari (AOU), 07100 Sassari, ItalyDepartment of Respiratory Diseases, University Hospital Sassari (AOU), 07100 Sassari, ItalyDepartment of Respiratory Diseases, University Hospital Sassari (AOU), 07100 Sassari, ItalyDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, ItalyDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, ItalyDiscipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, AustraliaDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, ItalyDepartment of Respiratory Diseases, University Hospital Sassari (AOU), 07100 Sassari, ItalyDepartment of Respiratory Diseases, University Hospital Sassari (AOU), 07100 Sassari, ItalyThere are increasing efforts to better predict adverse outcomes for idiopathic pulmonary fibrosis (IPF). Our aim was to assess the prognostic potential of ischemia-modified albumin (IMA), an established circulating marker of ischemia and, more recently, oxidative stress, in a cohort of 56 IPF patients recruited between 2015 and 2023 at the University of Sassari, Italy. Demographic and functional parameters and serum IMA concentrations were measured at baseline. Non-survivors had significantly higher IMA concentrations vs. survivors (508 ± 64 vs. 474 ± 42 mABSU, respectively; <i>p</i> = 0.035). The Kaplan–Meier analysis showed a significant association between higher IMA values and poor survival (HR: 3.32, 95% CI from 1.06 to 10.4, <i>p</i> = 0.039). In the Cox regression analysis, this association remained significant after adjusting for the force expiratory volume at 1 s, the total lung capacity, lymphocyte count, and pharmacological treatment (HR: 1.0154, 95% CI from 1.0035 to 1.0275, <i>p</i> = 0.01). IMA, an oxidative stress biomarker measurable using relatively simple and available methods, is independently associated with mortality in IPF. Therefore, its determination may enhance risk stratification and treatment decisions. Prospective studies involving larger cohorts are needed to confirm this association and to endorse the use of IMA in routine practice.https://www.mdpi.com/2076-3921/13/3/278ACB testIMAIPFsurvival |
| spellingShingle | Angelo Zinellu Stefano Zoroddu Simona Fois Sabrina Mellino Chiara Scala Erika Virdis Elisabetta Zinellu Salvatore Sotgia Panagiotis Paliogiannis Arduino A. Mangoni Ciriaco Carru Pietro Pirina Alessandro G. Fois Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study Antioxidants ACB test IMA IPF survival |
| title | Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study |
| title_full | Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study |
| title_fullStr | Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study |
| title_full_unstemmed | Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study |
| title_short | Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study |
| title_sort | ischemia modified albumin ima is associated with poor survival in patients with newly diagnosed idiopathic pulmonary fibrosis ipf a pilot study |
| topic | ACB test IMA IPF survival |
| url | https://www.mdpi.com/2076-3921/13/3/278 |
| work_keys_str_mv | AT angelozinellu ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT stefanozoroddu ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT simonafois ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT sabrinamellino ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT chiarascala ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT erikavirdis ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT elisabettazinellu ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT salvatoresotgia ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT panagiotispaliogiannis ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT arduinoamangoni ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT ciriacocarru ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT pietropirina ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy AT alessandrogfois ischemiamodifiedalbuminimaisassociatedwithpoorsurvivalinpatientswithnewlydiagnosedidiopathicpulmonaryfibrosisipfapilotstudy |